MenopausePhase 2NCT00962585
Efficacy and Safety of S-equol on Vasomotor Symptoms in Menopausal Patients
A Phase 2 study testing S-equol in people with Menopause, run by Ausio Pharmaceuticals, LLC at 9 sites in 2 countries.
Trial summary
The purpose of this study is to assess the safety and effectiveness of S-equol in menopausal patients with hot flushes and night sweats. Read more about this study
- Who is it for?
- Any age, women only
- Conditions the study is for
- Menopause
- What is being tested?
- S-equol
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 169 participants
- Where
- 9 sitesin 2 countries
- Study dates
- Jun 2010to Nov 2011
- Phase
- Phase 2
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- Women only
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- 12 months of spontaneous amenorrhea, or 6 months of spontaneous amenorrhea with serum follicle stimulating hormone (FSH) concentrations > 40 mIU/mL, or 6 weeks postsurgical bilateral oophorectomy with or without hysterectomy, or hysterectomy with 2 (measured 14 days apart) serum FSH concentrations > 40 mIU/mL.
- Is likely to experience at least 50 moderate to severe vasomotor symptoms ([MSVS] hot flushes and nocturnal sweating) per week while not receiving estrogen replacement therapy based on history of menopause, in the judgment of the investigator.
- Documented experiencing at least 50 MSVS per week during the 14 day baseline period before the Randomization Visit (Visit 3), based on the patient diary entries (calculated mean MSVS/week for the 14 day baseline period).
- If ≥ 40 years of age, has a documented negative mammogram and a normal clinical breast examination with no findings indicative of breast malignancy.
- Has a body mass index (BMI) < 35.0 kg/m2.
Who cannot join
- Has a known history of allergic reaction or clinically significant intolerance to ingredients of the study drug.
- Received any of the following:oral or dermal estrogen/progestin or selective estrogen receptor modulator (SERM) containing drug product therapy within 8 weeks before Screening, injectable or implantable estrogen/progestin therapy within 3 months before Screening, hormone releasing intrauterine device
- Had unexplained or otherwise abnormal vaginal bleeding within 6 months before Screening.
- Has a history of, or currently has, any of the following conditions: thrombophlebitis, thromboembolic disease, estrogen dependent neoplasia, or carcinoma of the breast.
- Has a history of any untreated or uncontrolled endocrine disorders (e.g., hyperparathyroidism, uncontrolled hyperthyroidism).
- Has any clinically significant unstable cardiac, respiratory, neurological, immunological, hematological, hepatic, renal, endocrine, or gastric disease or any other condition that, in the opinion of the investigator, could compromise the patient's welfare, ability to communicate with the study staff, or otherwise contraindicate study participation.
Show all 18Show fewer
- Has clinically significant depression or severe psychiatric disturbances.
- Has active liver disease with aspartate aminotransferase (AST) > 3 times the upper limit of normal (ULN), alanine aminotransferase (ALT) > 3 times ULN, unexplained alkaline phosphatase > 3 times ULN, total bilirubin > 2 times ULN, renal insufficiency with creatinine > 1.7 mg/dL, or clinically significant abnormal hemoglobin, white blood cell count, or platelet count.
- Has an endometrial thickness ≥ 4 mm.
- Has a history indicative of endometrial hyperplasia or cancer.
- Shows presence of any manifest premalignant or malignant disease except treated skin cancers (except melanoma).
- Has known or suspected history of alcoholism or drug abuse or misuse within the past 5 years.
- Has resting systolic blood pressure (BP) > 160 mmHg or < 90 mmHg, or diastolic BP > 90 mmHg or < 60 mmHg at Screening.
- Has a history of smoking more than 5 cigarettes daily within the year before Screening.
- Has tested positive on the urine drug screen. Patients who test positive at Screening and can produce documentation from their physician for the medication that caused the positive test may be considered for study enrollment at the discretion of the investigator.
- Has significant difficulties swallowing capsules or is unable to tolerate oral medication.
- Has participated in another clinical trial or received any investigational drug or device or investigational therapy within 30 days before Screening.
- Has a disorder that affects gastrointestinal absorption.
Trial locations and contacts
9 sites in 2 countries.
9 sites in 2 countries
United States5 sites
Greater Cincinnati OB/GYN, Inc.
Cincinnati, Ohio, 45267-0457
Rapid Medical Research
Cleveland, Ohio, 44122
Radiant Research, Inc
Greenville, South Carolina, 29621
Bluegrass Clinical Research
Louisville, Kentucky, 40291
Advanced Clinical Research
West Jordon, Utah, 84088
Australia4 sites
Women's Health Center, Royal Adelaide Hospital
Adelaide, South Australia, 5000
Sydney Centre for Reproductive Health Research
Ashfield, New South Wales, 2131
Emeritus Research
Malvern East, Victoria, 3144
Royal Hospital for Women
Randwick, New South Wales, 2031
About this study
Official title: Randomized, Double Blind, Multicenter, Placebo Controlled, Proof of Concept Trial to Assess the Efficacy and Safety of 4 Weeks Treatment With AUS-131 (S-equol) on Vasomotor Symptoms in Menopausal Patients
The purpose of this study is to assess the safety and effectiveness of S-equol in menopausal patients with hot flushes and night sweats.
Read the detailed description
The study is a randomized, double blind, multicenter, placebo controlled, parallel group, proof of concept study comparing the efficacy, safety, and acceptability of 3 doses of S-equol to placebo in menopausal patients with vasomotor symptoms. The study objective is an evaluation of the dose response of 3 dose levels of AUS-131 (S-equol) and placebo with respect to reducing the mean number of moderate to severe vasomotor symptoms after 4 weeks of treatment. The safety of S-equol will be evaluated during the study.
- Conditions
- Menopause
- Being tested
- Placebo, S-equol
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
PlaceboDrug
S-equolDrug
Also called AUS-131
Eligible patients meeting all study entry criteria were randomly assigned to receive one of the following active treatments for 4 weeks:
- S-equol 10 mg BID (20 mg total daily dose)
- S-equol 50 mg BID (100 mg total daily dose)
- S-equol 150 mg BID (300 mg total daily dose)
| Study group | Role | What they receive |
|---|---|---|
| Placebo | Placebo comparator | Placebo Receives: Drug: Placebo |
| S-equol 10 mg BID | Experimental | S-equol 20 mg total daily dose Receives: Drug: S-equol |
| S-equol 50 mg BID | Experimental | S-equol 100 mg total daily dose Receives: Drug: S-equol |
| S-equol 150 mg BID | Experimental | S-equol 300 mg total daily dose Receives: Drug: S-equol |
What is being measured
The primary outcome is the main question the study is designed to answer.
Mean Change in Frequency of Moderate to Severe Vasomotor Symptoms (MSVS) Baseline at Week 4 (2-week Period)
The primary efficacy endpoint for this study was the change from Baseline (Day 0) in the frequency of MSVS (difference between Baseline [2-week run-in period] and Week 4), where the baseline MSVS frequency was captured over 14 ± 2 day period. Moderate is defined as "sensation of heat with sweating, able to continue activity"; severe is defined as "sensation of heat with sweating, causing cessation of activity". Patients used the take-home daily diary to record MSVS information during the run-in period and treatment period and analyses were performed as specified.
Treatment group differences are estimated using least squares (LS) means and 95% confidence intervals based on the mean square error from the ANCOVA. LSMeans refer to overall adjusted mean frequency of MSVS.
Measured: 4 weeks from Baseline (2-week run-in period)
Secondary outcomes (9)
Mean Change in Frequency of MSVS From Baseline at Week 4 (1-week Period)
Change from Baseline in the frequency of MSVS (difference between Baseline [period following first 7 days of 2-week run-in period] and period following first 7 days of 2-week Week 4 period), where the Baseline MSVS frequency was captured at visit 3 (Day 0), in the period following the first 7 days, as per CRF. Note: this endpoint is identical to the primary endpoint, however, instead of a 14 ± 2 day period, the period following the first 7 days was used, at Baseline and visit 3.
Treatment group differences are estimated using least squares (LS) means and 95% confidence intervals based on the mean square error from the ANCOVA. LSMeans refer to overall adjusted mean frequency of MSVS.
Measured: 4 weeks from Baseline (period following first 7 days of 2-week run-in period)
Change From Baseline (Day 0) in the Frequency of MSVS at Week 1 and Week 2
The frequency of MSVS per week, at each of the protocol visits, was calculated as follows, for each patient: [# of Moderate+Severe hot flushes)/(Current protocol visit date-Previous protocol visit date (days)] * 7.
The ANCOVA procedure tested the following hypotheses:
H0: μ1 = μp versus HA: μ1 ≠ μp, where μ1 and μp denote the mean frequency of MSVS, adjusted for Baseline MSVS values, in the treatment and placebo groups, respectively.
LSMeans refer to the overall adjusted mean frequecy of MSVS.
Measured: 1 and 2 weeks from Baseline (Day 0)
Change From Baseline (Day 0) in the Severity of VMS as Recorded in the Patient Diary at Week 1, Week 2, and Week 4
The severity of vasomotor symptoms per week at each of the protocol visits was calculated for each patient as follows: [(Sum of scores of Mild, Moderate, Severe hot flushes)/(Current protocol visit date - Previous protocol visit date (days)] * 7, where severity of vasomotor symptoms were scored as: 1 = mild, 2 = moderate and 3 = severe. Higher values represented worse severity.
LSMeans refer to the overall adjusted mean severity of VMS.
Hot Flush Classification: Mild: sensation of heat without sweating; Moderate: sensation of heat with sweating, able to continue activity; Severe: sensation of heat with sweating, causing cessation of activity.
Patients recorded the number of hot flushes (day and night) in their diaries related to the severity (mild/moderate/severe).
Measured: 1, 2, and 4 weeks from Baseline (Day 0)
Change From Baseline (Day 0) in Vaginal pH at Week 2 and Week 4
The pH scale measures how acidic or basic a substance is. The pH scale ranges from 0 to 14. A pH of 7 is neutral. A pH less than 7 is acidic. A pH greater than 7 is basic. The pH scale is logarithmic and as a result, each whole pH value below 7 is ten times more acidic than the next higher value.
Normal vaginal pH is 3.8 to 4.5, slightly acidic.
The LSMeans refer to overall adjusted mean pH.
Measured: 2 and 4 weeks from Baseline (Day 0)
Change From Baseline in Vaginal Maturation Index at Week 2 and Week 4
The Vaginal Maturation Index was calculated by examining the maturation of the vaginal epithelium as adjudged by the cell types exfoliated. Parabasal cells are the least mature cells, intermediate cells display mild maturation, and superficial cells display the most maturity. The cell count is expressed as a percentage. The Vaginal Maturation Index was calculated as: 0.2*(parabasal cells, %)+0.6*(intermediate cells, %)+1.0*(superficial cells, %). This method is described in Menopause 2005;12(6):708-15.
The index serves as an objective means of evaluating hormonal secretion or response; lower values indicate more immature cells on the surface (atrophy), while higher values indicate more mature epithelium.
The LSMeans refer to overall adjusted mean percent of cells counted.
Measured: 2 and 4 weeks from Baseline (Day 0)
Change From Baseline in Estradiol Concentration at Weeks 2 and 4
The LSMeans refer to overall adjusted mean estradiol concentration.
Measured: 2 and 4 weeks from Baseline (Day 0)
Change From Baseline in Progesterone Concentration at Week 2 and Week 4
No repeated measures ANCOVA results are presented for change from Baseline in progesterone concentrations since the model did not converge.
Measured: 2 and 4 weeks from Baseline (Day 0)
Mean Change in the Menopause Rating Scale Total Score From Baseline at Week 4
MRS consists of 11 menopause symptoms. The scoring scheme is simple, i.e., the score increases point by point with increasing severity of subjectively perceived symptoms in each of the 11 items (severity 0 [no complaints] 4 scoring points [extremely severe symptoms]). The respondent provides her personal perception by checking one of 5 possible boxes of "severity" for each of the items. The composite score (total score) is the sum of the 11 item scores, which can range from 0 (no symptoms) to 44 (extremely severe symptoms). Low total scores represent less severe menopause symptoms while higher scores represent more severe symptoms.
Measured: 4 weeks from Baseline (Day 0)
Mean Precentage Change in the Menopause Rating Scale Total Score From Baseline at Week 4
Percentage change from Baseline at Week 4 = (Week 4 value - Day 0 value)/(Day 0 value) x 100. Note: MRS consists of 11 symptoms, where each symptom is assigned a score from 0 to 4 (0 = 'None' and 4 = 'Extremely severe').
Measured: 4 weeks from Baseline (Day 0)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Aug 2009 (estimated)
- Study startJun 2010
- Primary completionNov 2011
- Study completionNov 2011
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for MenopauseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 169 participants (actual)
Sponsor and investigators
- Lead sponsor
- Ausio Pharmaceuticals, LLC
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Michael A Thomas, MD, Principal investigator, University of Cincinnati
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00962585
- Sponsor's protocol ID
- AUS-CT03
- Status last verified
- Mar 2014
- First submitted
- 19 Aug 2009
- Last updated
- 8 Apr 2014
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 8 Apr 2014. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Randomized, Double Blind, Multicenter, Placebo Controlled, Proof of Concept Trial to Assess the Efficacy and Safety of 4 Weeks Treatment With AUS-131 (S-equol) on Vasomotor Symptoms in Menopausal Patients
- ClinicalTrials.gov ID
- NCT00962585
- Acronym / sponsor ID
- AUS-CT03
- Conditions
- Menopause
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 169 participants (actual)
- Lead sponsor
- Ausio Pharmaceuticals, LLCIndustry (pharma, biotech, devices)
- Study start
- Jun 2010
- Primary completion
- Nov 2011 (actual)
- Study completion
- Nov 2011 (actual)
- First posted
- 20 Aug 2009 (estimated)
- Results
- Posted 8 Apr 2014
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to assess the safety and effectiveness of S-equol in menopausal patients with hot flushes and night sweats.
Detailed description
The study is a randomized, double blind, multicenter, placebo controlled, parallel group, proof of concept study comparing the efficacy, safety, and acceptability of 3 doses of S-equol to placebo in menopausal patients with vasomotor symptoms. The study objective is an evaluation of the dose response of 3 dose levels of AUS-131 (S-equol) and placebo with respect to reducing the mean number of moderate to severe vasomotor symptoms after 4 weeks of treatment. The safety of S-equol will be evaluated during the study.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Placebo | Placebo comparator | Drug: PlaceboPlacebo |
| S-equol 10 mg BID | Experimental | Drug: S-equolS-equol 20 mg total daily dose |
| S-equol 50 mg BID | Experimental | Drug: S-equolS-equol 100 mg total daily dose |
| S-equol 150 mg BID | Experimental | Drug: S-equolS-equol 300 mg total daily dose |
Who may qualify
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (5 listed)
- 12 months of spontaneous amenorrhea, or 6 months of spontaneous amenorrhea with serum follicle stimulating hormone (FSH) concentrations > 40 mIU/mL, or 6 weeks postsurgical bilateral oophorectomy with or without hysterectomy, or hysterectomy with 2 (measured 14 days apart) serum FSH concentrations > 40 mIU/mL.
- Is likely to experience at least 50 moderate to severe vasomotor symptoms ([MSVS] hot flushes and nocturnal sweating) per week while not receiving estrogen replacement therapy based on history of menopause, in the judgment of the investigator.
- Documented experiencing at least 50 MSVS per week during the 14 day baseline period before the Randomization Visit (Visit 3), based on the patient diary entries (calculated mean MSVS/week for the 14 day baseline period).
- If ≥ 40 years of age, has a documented negative mammogram and a normal clinical breast examination with no findings indicative of breast malignancy.
- Has a body mass index (BMI) < 35.0 kg/m2.
Key exclusion criteria (18 listed)
- Has a known history of allergic reaction or clinically significant intolerance to ingredients of the study drug.
- Received any of the following:oral or dermal estrogen/progestin or selective estrogen receptor modulator (SERM) containing drug product therapy within 8 weeks before Screening, injectable or implantable estrogen/progestin therapy within 3 months before Screening, hormone releasing intrauterine device
- Had unexplained or otherwise abnormal vaginal bleeding within 6 months before Screening.
- Has a history of, or currently has, any of the following conditions: thrombophlebitis, thromboembolic disease, estrogen dependent neoplasia, or carcinoma of the breast.
- Has a history of any untreated or uncontrolled endocrine disorders (e.g., hyperparathyroidism, uncontrolled hyperthyroidism).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Placebo | Drug | Placebo |
| S-equolAlso: AUS-131Eligible patients meeting all study entry criteria were randomly assigned to receive one of the following active treatments for 4 weeks: * S-equol 10 mg BID (20 mg total daily dose) * S-equol 50 mg BID (100 mg total daily dose) * S-equol 150 mg BID (300 mg total daily dose) | Drug | S-equol 10 mg BID, S-equol 150 mg BID, S-equol 50 mg BID |
Primary outcome
Mean Change in Frequency of Moderate to Severe Vasomotor Symptoms (MSVS) Baseline at Week 4 (2-week Period)
Time frame: 4 weeks from Baseline (2-week run-in period)
The primary efficacy endpoint for this study was the change from Baseline (Day 0) in the frequency of MSVS (difference between Baseline [2-week run-in period] and Week 4), where the baseline MSVS frequency was captured over 14 ± 2 day period. Moderate is defined as "sensation of heat with sweating, able to continue activity"; severe is defined as "sensation of heat with sweating, causing cessation of activity". Patients used the take-home daily diary to record MSVS information during the run-in period and treatment period and analyses were performed as specified. Treatment group differences are estimated using least squares (LS) means and 95% confidence intervals based on the mean square error from the ANCOVA. LSMeans refer to overall adjusted mean frequency of MSVS.
9 secondary outcomes
Mean Change in Frequency of MSVS From Baseline at Week 4 (1-week Period)
Time frame: 4 weeks from Baseline (period following first 7 days of 2-week run-in period)
Change From Baseline (Day 0) in the Frequency of MSVS at Week 1 and Week 2
Time frame: 1 and 2 weeks from Baseline (Day 0)
Change From Baseline (Day 0) in the Severity of VMS as Recorded in the Patient Diary at Week 1, Week 2, and Week 4
Time frame: 1, 2, and 4 weeks from Baseline (Day 0)
Change From Baseline (Day 0) in Vaginal pH at Week 2 and Week 4
Time frame: 2 and 4 weeks from Baseline (Day 0)
Change From Baseline in Vaginal Maturation Index at Week 2 and Week 4
Time frame: 2 and 4 weeks from Baseline (Day 0)
Change From Baseline in Estradiol Concentration at Weeks 2 and 4
Time frame: 2 and 4 weeks from Baseline (Day 0)
Change From Baseline in Progesterone Concentration at Week 2 and Week 4
Time frame: 2 and 4 weeks from Baseline (Day 0)
Mean Change in the Menopause Rating Scale Total Score From Baseline at Week 4
Time frame: 4 weeks from Baseline (Day 0)
Mean Precentage Change in the Menopause Rating Scale Total Score From Baseline at Week 4
Time frame: 4 weeks from Baseline (Day 0)
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Apr 2014.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
Related trials for Menopause
Recruiting
Hop Extract Versus Soy Isoflavone Extract for Menopausal Symptoms (HOPES)
Menopause, Perimenopause
Not yet recruiting
The Role of Diet Quality in Sleep Among Women in Postmenopause
Post Menopausal Women
Active, not recruitingPhase 3
Human Menopausal Gonadotropin Research in Infertility Assessing Cumulative Live Birth With Frozen Embryo Transfer.
Infertility (IVF Patients)
Not yet recruiting
Effect of Hormone Replacement Therapy on Physiotherapy Outcomes in Postmenopausal Women With Frozen Shoulder
Frozen Shoulder, Adhesive Capsulitis
RecruitingObservational study
Observational Study of Bone Complications in People With Post-menopausal Breast Cancer Who Have Stopped Treatment With Denosumab and Aromatase Inhibitors
Breast Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Michael A Thomas, MD principal investigator
University of Cincinnati
9 sites in 2 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing S-equol in people with Menopause, run by Ausio Pharmaceuticals, LLC at 9 sites in 2 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 18 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 8 Apr 2014. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 9 sites in United States, Australia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 8 Apr 2014). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Mean Change in Frequency of Moderate to Severe Vasomotor Symptoms (MSVS) Baseline at Week 4 (2-week Period) (time frame: 4 weeks from Baseline (2-week run-in period)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Apr 2014.